Skip to main content
. 2023 Sep 22;8(18):e167790. doi: 10.1172/jci.insight.167790

Figure 7. Denosumab does not increase osteoclast progenitors.

Figure 7

(A) Left panel: In vitro osteoclast formation using bone marrow from 7-month-old female mice treated with vehicle (Veh) or denosumab (Dmab; 10 mg/kg every 2 weeks). Bone marrow was isolated 2 weeks after the last of 4 injections. Bone marrow from each mouse was cultured in 3 wells and each symbol represents the average osteoclast number of triplicate wells. Right panel: Acp5 mRNA levels in RNA from freshly isolated bone marrow of the same mice described in the left panel. In both panels, bars and whiskers represent the mean ± SD of 4 mice and P values were determined by 2-tailed unpaired t test. (B) As in A, except 10-month-old male mice were used. (C) UMAPs from scRNA-Seq analysis of Cd11b+ bone marrow cells isolated from 13-month-old male mice treated the same as in A. (D) UMAPs showing expression of genes highly expressed in osteoclasts. Each panel contains data from vehicle- and denosumab-treated mice. (E) Comparison of relative cell numbers from each cluster shown in C. (F) Violin plots of cells in the Macrophage_I cluster for genes highly expressed in osteomorphs. prolif., proliferative; prog., progenitors.